GC-1 (Sobetirome)

GC-1, also called sobetirome, attracts people looking for thyroid-like fat loss with less heart strain or muscle loss than T3. The discussion contains enthusiastic claims and reports of flat energy or a low-thyroid crash, but little independently documented experience. Selective thyroid activity does not mean no suppression.

What GC-1 is

• A synthetic thyroid mimic, also called QRX-431. Sobetirome is a non-peptide compound designed to produce selected thyroid-hormone effects. It favors the beta thyroid receptor; “selective” describes a preference, not a guarantee that other tissues or the body’s thyroid feedback system are unaffected. Official context Official context Animal context
• T3 and T4 are the nearest useful comparisons. Liothyronine supplies T3; levothyroxine supplies T4, which the body can convert to T3. GC-1 stimulates thyroid receptors with a different molecule. The forum question about replacing thyroid medication therefore involves more than finding an equivalent number of micrograms. MESO-Rx Official context Official context
• Sob-AM2 is a different research form. The mouse study compares parent sobetirome with a prodrug designed to change delivery toward the central nervous system. Results for that prodrug cannot simply be assigned to a bottle labeled GC-1. Animal context

What people hope to get

• The hope: fat loss with less muscle loss. The 2019 AnabolicMinds question starts with a supplier’s safer-T3 pitch. Replies challenge whether the cited research actually supports a metabolic benefit. That disagreement is about evidence; nobody in that thread demonstrates GC-1 fat loss or muscle preservation. AnabolicMinds
• A cleaner feeling, according to one author. Biohackingu claims metabolic and fat-loss benefits with less of T3’s unwanted feeling. The same author also describes worse low-thyroid crashes at high amounts. These are mixed personal/client assertions without individual measurements, not separate confirmations of benefit and safety. Personal report

Doses people discuss

• 25 mcg, possibly 37.5 mcg: one proposed combination. Luke391 proposes those GC-1 amounts with 5–10 mcg T3 and 50 mcg T4. Route and frequency are unstated, and no GC-1 result follows. These are proposed amounts, not an established daily range. MESO-Rx
• 50–100 mcg/day oral: a forum author’s suggestion. The 2026 Anabolic Steroid Forums author proposes 50, then 100 mcg/day and potentially beyond, while admitting experience is scarce. This is opinion, not a completed-use log or a safe starting or upper amount. Anabolic Steroid Forums
• The 100–300 figure has a disputed unit. Biohackingu prints 100–300 mg/day; Shadjanale says it should read mcg/day. The opening post also prints a 500 mg-plus suppression claim. Milligrams and micrograms differ by 1,000, and neither statement provides verified exposure records. This unit-conflicted post cannot establish a usable dose band or suppression threshold. Reddit r/BiohackingU

Half-life

• No traceable community half-life established. The inspected discussions do not identify a usable numerical GC-1 elimination half-life with a clear origin. A daily-use suggestion does not measure clearance; T3’s or T4’s timing cannot be borrowed for GC-1. AnabolicMinds MESO-Rx Low-Toxin BioEnergetic Forum

When people notice a change

• No dependable first-dose timeline. The personal/coach summaries describe metabolic drive or flatter energy but give no elapsed time from starting. They cannot tell a reader whether a noticeable change begins within hours, days or weeks. Reddit r/BiohackingU Personal report

How long the effects feel noticeable

• The crash report has no clock attached. Biohackingu describes a harsher low-thyroid feeling at high amounts, without a defined dose-to-symptom interval or recovery time. It is unclear whether the account concerns ongoing exposure, withdrawal, or both; it cannot establish daily felt duration or an after-stopping window. Personal report

Courses, breaks and long-term use

• Eight weeks is a proposed ceiling, not a proven cycle. The 2026 forum author suggests an eight-week maximum because longer use is uncertain. No completed cycle or recovery log supports that boundary. Anabolic Steroid Forums
• Long-term replacement remains a question. The MESO-Rx author asks about ongoing thyroid replacement but supplies no GC-1 follow-up. The inspected material establishes neither a repeat-cycle calendar nor a reliable break or recovery interval. MESO-Rx

What deserves caution

• Low energy contradicts the simple “more metabolism” story. The earlier Biohackingu post describes low drive and flat energy attributed to suppression in unnamed athletes. Its advice to add thyroid medication is not evidence that a combination prevents that problem; it also makes attribution harder. Reddit r/BiohackingU
• No-suppression marketing overstates the evidence. In a primary male-mouse experiment, repeated sobetirome exposure depleted circulating T3 and T4 while TSH remained normal. That is a reason to reject a blanket no-suppression promise, not a prediction of how often a person will experience it. Animal context
• Heart and muscle protection are not established human guarantees. Community interest centers on avoiding T3 tradeoffs, but the inspected accounts do not document long-term cardiac, muscle or bone outcomes. A thyroid-receptor preference cannot certify safety. AnabolicMinds Personal report
• Orphan designation is not approval. The FDA record lists a designation for X-linked adrenoleukodystrophy and explicitly says it is not approved for that orphan indication. That record does not authorize bodybuilding or thyroid-replacement use. Official context

What the discussions actually add

• The hoped-for benefit and the existing stack are different facts. Luke391 already reports tirzepatide and L-carnitine use with improved body-fat control, while energy remains poor. GC-1 is still only a plan. Crediting those earlier body changes to sobetirome would reverse the timeline. MESO-Rx
• An order is not a result. FearsomeCOR initially says GC-1 is on the way and confirms no prior experience. Later in the thread, that same person distinguishes selective GC-1 action from full thyroid replacement. Neither post supplies a successful trial. The Board Rep label and promotional opening also matter when weighing confidence. Anabolic Steroid Forums
• Different posts can still be one evidence source. Both BiohackingU write-ups are by Biohackingu. Their personal and client accounts remain one connected source family. The later comparison emphasizes a crash; it does not provide independent corroboration of the earlier benefits. Reddit r/BiohackingU Personal report
• Interest has outlasted detailed public follow-up. A 2021 Low-Toxin forum question frames GC-1 as T3-like with fewer side effects; a 2022 reply asks whether the experiment ever happened. A 2025 bump asserts metabolic and bile-acid effects without reporting use. None supplies a documented positive or negative response, and sparse follow-up cannot establish a success rate. Low-Toxin BioEnergetic Forum